Table 1.
Demographics, transplant history timeline of symptoms, testing, resolution, and adverse events
| Demographics, timelines, and adverse events | Value or %, N = 24 |
|---|---|
| Age, yr, median (range) | 53.1 (36.3–76.6) |
| Gender, n (%) | |
| Male | 15 (62.5) |
| Female | 9 (37.5) |
| Race, n (%) | |
| Caucasian | 19 (79.2) |
| African American | 4 (16.6) |
| Hispanic | 1 (4.2) |
| Kidney transplant, n (%) | |
| Living donor | 10 (41.7) |
| Deceased donor | 14 (58.3) |
| Combined transplants, n | |
| Kidney and pancreas | 3 |
| Heart and kidney | 1 |
| Liver and kidney | 1 |
| Comorbidities, n (%) | |
| Hypertension | 19 (79.2) |
| Hyperlipidemia | 11 (45.8) |
| Diabetes mellitus (types I and II) | 7 (29.2) |
| Asthma | 3 (12.5) |
| Hypothyroidism | 4 (16.7) |
| Coronary artery disease | 3 (12.5) |
| Median time from transplant to COVID-19, days (range) | 1610 (19–11,884) |
| Baseline creatinine before COVID-19, mg/dl ± SD | 1.43 ± 0.46 |
| Median ± SD time from symptom onset to COVID-19 testing, days (median [range]) | 2.08 ± 1.2 (2 [0–4]) |
| Median ± SD time from SARS CoV-2 PCR test result to infusion,a days | 2.67 ± 2.5 (1.5 [0–9]) |
| Median ± SD time from onset of symptoms to infusion,a days | 4.75 ± 2.3 (4 [2–8]) |
| Major symptoms, n (%) | |
| Fatigue | 15 (62.5) |
| Fever | 12 (50) |
| Cough | 9 (37.5) |
| Anosmia/dysgeusia | 4 (16.7) |
| Chills | 4 (16.7) |
| Headache | 4 (16.7) |
| Shortness of breath | 4 (16.7) |
| Sore throat/sinus congestion | 3 (12.5) |
| Pre–COVID-19 immunosuppressive regimen | |
| Tacrolimus/mycophenolic acid | 13 (54.2) |
| Tacrolimus/mycophenolic acid/prednisone | 4 (16.7) |
| Tacrolimus/sirolimus | 3 (12.5) |
| Tacrolimus/sirolimus/mycophenolic acid | 1 (4.2) |
| Mycophenolic/prednisone | 1 (4.2) |
| Other | 2 (8.3) |
| Post–COVID-19 immunosuppressive regimen | |
| No change to regimen | 13 (54.2) |
| Decrease mycophenolic acid by ≥50% | 7 (29.2) |
| Hold mycophenolic acid | 4 (16.7) |
| Adverse events from infusion, n (%) | |
| Nausea | 2 (8.3) |
| Headache | 2 (8.3) |
| Rash on fingers that resolved within 2–3 days | 1 (4.2) |
| No side effects noted, % | 87.5 |
| Median ± SD time to resolution of symptoms reported (among those who reported improvement), hours (median [range]) | 31.4 ± 15.9 (24 [12–72]), n = 14 |
| No improvement, n (%) | 6 (26.1) |
| Other symptoms improved but fever for 30 days, n (%) | 1 (4.2) |
| Fatigue for 30 days, n (%) | 1 (4.2) |
| Fever 14 days, n (%) | 1 (4.2) |
| Unable to recall, n (%) | 1 (4.2) |
PCR, polymerase chain reaction; SD, standard deviation.
a
Bamlanivimab infusion